Daewoong Pharmaceutical - Public Comps and Valuation Multiples

Daewoong Pharmaceutical Overview

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Founded

2002

HQ

Employees

n/a

Website

daewoong.co.kr

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.0B

LTM EBITDA $168M

EV

$1.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Daewoong Pharmaceutical Financials

As of December 2025, Daewoong Pharmaceutical reported last 12-month revenue of $1.0B and EBITDA of $168M.

In the same period, Daewoong Pharmaceutical generated $546M in LTM gross profit and $97.9M in net income.

See Daewoong Pharmaceutical valuation multiples based on analyst estimates

Daewoong Pharmaceutical P&L

In the most recent fiscal year, Daewoong Pharmaceutical reported revenue of $982M and EBITDA of $77.7M.

Daewoong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Daewoong Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$1.0B	XXX	$982M	XXX	XXX	XXX
Gross Profit	$546M	XXX	$507M	XXX	XXX	XXX
Gross Margin	53%	XXX	52%	XXX	XXX	XXX
EBITDA	$168M	XXX	$77.7M	XXX	XXX	XXX
EBITDA Margin	16%	XXX	8%	XXX	XXX	XXX
EBIT	$138M	XXX	$102M	XXX	XXX	XXX
EBIT Margin	13%	XXX	10%	XXX	XXX	XXX
Net Profit	$97.9M	XXX	$17.1M	XXX	XXX	XXX
Net Margin	9%	XXX	2%	XXX	XXX	XXX
Net Debt	XXX	XXX	$375M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Daewoong Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.0B. EBITDA for the last twelve months was $168M. In the most recent fiscal year, Daewoong Pharmaceutical achieved $982M in revenue and $77.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$1.0B	Analyst estimates available to subscribers	$982M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$546M	Analyst estimates available to subscribers	$507M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	52.7% gross margin	Analyst estimates available to subscribers	51.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$168M	Analyst estimates available to subscribers	$77.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	16.2% EBITDA margin	Analyst estimates available to subscribers	7.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$138M	Analyst estimates available to subscribers	$102M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	13.4% EBIT margin	Analyst estimates available to subscribers	10.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$97.9M	Analyst estimates available to subscribers	$17.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	9.4% net profit margin	Analyst estimates available to subscribers	1.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$375M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Daewoong Pharmaceutical

This financial data table provides comprehensive performance metrics for Daewoong Pharmaceutical, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Daewoong Pharmaceutical generated $1.0B in revenue over the last twelve months.
The company achieved $168M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $546M.
Net income over the last twelve months reached $97.9M.

Fiscal Year Performance

In the most recent fiscal year, Daewoong Pharmaceutical reported $982M in total revenue.
Fiscal year EBITDA was $77.7M.
The company maintained a gross profit margin of 51.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 7.9%.
Net profit margin reached 1.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Daewoong Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Daewoong Pharmaceutical Stock Performance

Daewoong Pharmaceutical has current market cap of KRW 1.89T (or $1.3B), and EV of KRW 2.47T (or $1.7B).

Market Cap Evolution

Daewoong Pharmaceutical Stock Data

As of January 16, 2026, Daewoong Pharmaceutical's stock price is KRW 164200 (or $113).

See Daewoong Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.7B	$1.3B	XXX	XXX	XXX	XXX	$8.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Daewoong Pharmaceutical Valuation Multiples

Daewoong Pharmaceutical's trades at 1.6x EV/Revenue multiple, and 10.2x EV/EBITDA.

See valuation multiples for Daewoong Pharmaceutical and 15K+ public comps

Daewoong Pharmaceutical Financial Valuation Multiples

As of January 16, 2026, Daewoong Pharmaceutical has market cap of $1.3B and EV of $1.7B.

Equity research analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Daewoong Pharmaceutical has a P/E ratio of 13.3x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$1.3B	XXX	$1.3B	XXX	XXX	XXX
EV (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV/Revenue	1.6x	XXX	1.6x	XXX	XXX	XXX
EV/EBITDA	10.2x	XXX	10.2x	XXX	XXX	XXX
EV/EBIT	12.3x	XXX	12.3x	XXX	XXX	XXX
EV/Gross Profit	3.1x	XXX	n/a	XXX	XXX	XXX
P/E	13.3x	XXX	13.3x	XXX	XXX	XXX
EV/FCF	23.7x	XXX	23.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Daewoong Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Daewoong Pharmaceutical Margins & Growth Rates

Daewoong Pharmaceutical's last 12 month revenue growth is 8%

Daewoong Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Daewoong Pharmaceutical's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Daewoong Pharmaceutical's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Daewoong Pharmaceutical and other 15K+ public comps

Daewoong Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	8%	XXX	9%	XXX	XXX	XXX
EBITDA Margin	16%	XXX	16%	XXX	XXX	XXX
EBITDA Growth	3%	XXX	17%	XXX	XXX	XXX
Rule of 40	21%	XXX	24%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	37%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	17%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	41%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial